Business
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline VANCOUVER, Wash. and NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- A
About this update from Absci Corporation
[{"type":"image","alt":"Absci Corporation","displaySize":"","headline":null,"caption":"Absci Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/42d59199135e8e78f2ae46a2458d8373"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z7BN4y4UBod826Tg9AseVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMw--/https://media.zenfs.com/en/globenewswire.com/42d59199135e8e78f2ae46a2458d8373","width":300,"height":88}},"lazy":false},{"type":"text","content":"Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data","length":152,"tagName":"p"},{"type":"text","content":"Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval","length":109,"tagName":"p"},{"type":"text","content":"Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial","length":91,"tagName":"p"},{"type":"text","content":"Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline","length":83,"tagName":"p"},{"type":"text","content":"VANCOUVER, Wash. and NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended March 31, 2026.","length":290,"tagName":"p"},{"type":"text","content":"“2026 is going to be a data-rich year for Absci with multiple readouts ahead,” said Sean McClain, Founder and CEO. “ABS-201, our AI-designed long-acting antibody against the prolactin receptor, has the potential to be the first new mechanism of action in androgenetic alopecia in nearly three decades, with a targeted dosing interval of just a few times a year. ABS-202, announced today, extends our prolactin work into a third therapeutic area. We're combining Origin with the prolactin biology we've built to go after a target that has been overlooked.”","length":563,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Successfully dosed all four planned healthy volunteer single ascending dose (SAD) cohorts of ongoing Phase 1/2a HEADLINE trial. ...